+

WO1997029770A1 - Vaccin contre la sarcocystose - Google Patents

Vaccin contre la sarcocystose Download PDF

Info

Publication number
WO1997029770A1
WO1997029770A1 PCT/AU1996/000419 AU9600419W WO9729770A1 WO 1997029770 A1 WO1997029770 A1 WO 1997029770A1 AU 9600419 W AU9600419 W AU 9600419W WO 9729770 A1 WO9729770 A1 WO 9729770A1
Authority
WO
WIPO (PCT)
Prior art keywords
bradozooids
vaccine
toxin
protozoa
sarcocystis
Prior art date
Application number
PCT/AU1996/000419
Other languages
English (en)
Inventor
Jose Luis Azumendi
Original Assignee
Sarco Research Corporation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarco Research Corporation Limited filed Critical Sarco Research Corporation Limited
Priority to AU62938/96A priority Critical patent/AU6293896A/en
Publication of WO1997029770A1 publication Critical patent/WO1997029770A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens

Definitions

  • the present invention relates to a vaccine for immunisation against infections caused by the toxin of the Sarcocystis protozoa in the hosts of the parasite, as well as by toxins which are closely related in chemical structure and physiological effect to such toxin.
  • the present invention also relates to a method for producing the vaccine.
  • the present invention is based on research developed by us on infections due to toxicogenic Sarcocystis, which are able to provide the toxin (Sarcocystine). It has been found that the toxin has the capacity to alter the normal function of blood microcirculation of B and T lymphocytes and the coagulation factors of blood, producing a chronic passive congestion with extravasation of liquids and solids in the form of oedema and or haemorrhage in the different organs that are irrigated dirough blood microcirculation.
  • the central nervous system because the blood never comes in contact with the myelin, thanks to the system of the hematoencephalic barrier (HB), it is clear that if a patient presents with Sarcocystine, then oedemas and/or haemorrhages will be produced in the CNS. This leads us to conclude that the toxin is capable of breaking through the HB, and of increasing the blood lymphocyte count by its mitogenic capacity. In addition the parasite toxin has the capacity to increase the concentrations of the tumoral necrosing factor. When the toxin is administered in experimental infections it has been possible to reproduce demyelinating lesions, even developing Central Nervous System dysfunctions, hemiplegia, paraplegia and quadriplegia.
  • the vaccines may also include other agents conventional in the art having regard to the mode of administration, for example, those suitable for oral administration may include such further agents as binders, sweeteners, thickeners, flavouring agents, disintegrating agents, coating agents, preservatives, lubricants and/or time delay agents.
  • those suitable for oral administration may include such further agents as binders, sweeteners, thickeners, flavouring agents, disintegrating agents, coating agents, preservatives, lubricants and/or time delay agents.
  • at least one pharmaceutically acceptable sugar is present.
  • the parasite bradozooids are extracted from the muscle tissue by artificial digestion by pancreatic trypsin and they are then purified by density gradients with Percol
  • Percol is colloidal polyvinyl pyrrolidone "PVP" coated silica particles which are known in the art for the purpose of cell separation.
  • a formulation is preferably made as follows: -
  • the present invention provides a vaccine which is effective in humans against the Sarcocystine toxin and toxins of a like kind. Experiments with male New Zealand rabbits have already established the viability of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un vaccin pour immuniser contre les infections produites par les protozoaires du genre Sarcocystis, contenant des bradozooïdes lyophilisés et inactivés de protozoaires du genre Sarcocystis, ainsi qu'un vecteur acceptable sur le plan pharmaceutique. L'invention concerne également un procédé pour produire le vaccin.
PCT/AU1996/000419 1996-02-16 1996-07-05 Vaccin contre la sarcocystose WO1997029770A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62938/96A AU6293896A (en) 1996-02-16 1996-07-05 Sarcocystis vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9603303A GB2310135A (en) 1996-02-16 1996-02-16 Sarcocystis vaccine:lyophilized bradyzoites
GB9603303.0 1996-02-16

Publications (1)

Publication Number Publication Date
WO1997029770A1 true WO1997029770A1 (fr) 1997-08-21

Family

ID=10788893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1996/000419 WO1997029770A1 (fr) 1996-02-16 1996-07-05 Vaccin contre la sarcocystose

Country Status (3)

Country Link
AU (1) AU6293896A (fr)
GB (1) GB2310135A (fr)
WO (1) WO1997029770A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169398B2 (en) * 2000-04-25 2007-01-30 Wyeth Equine protozoal myeloencephalitis vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF VETERINARY RESEARCH, Volume 51, No. 7, issued July 1990, D.E. GRANSTROM et al., "Immunodominant Proteins of S. Cruzi Bradyzoites Isolated from Cahle Affected or Non Affected with Cosinophilic Myositis", pages 1151-1155. *
THE JOURNAL OF PARASITOLOGY, Volume 77, No. 2, issued April 1991, A.M. TENTER et al., "Effect of Tryptic or Peptic Digestion or Mechanical Isolation on the Extraction of Proteins, Antigens and Ribonucleic Acids From S. Muris Bradyzoites", pages 194-199. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169398B2 (en) * 2000-04-25 2007-01-30 Wyeth Equine protozoal myeloencephalitis vaccine

Also Published As

Publication number Publication date
GB9603303D0 (en) 1996-04-17
AU6293896A (en) 1997-09-02
GB2310135A (en) 1997-08-20

Similar Documents

Publication Publication Date Title
Sabin The filtrable microörganisms of the pleuropneumonia group
JPH08231425A (ja) トリの抗体を用いた哺乳動物の受動免疫化
JPH09512708A (ja) グルカンの酵素処理
CN1037276A (zh) 具有抗体活性和广谱作用的产品,由它们组成的或含有它们的药物,应用它们治疗与细菌或毒素有关的疾病、应用它们杀灭原虫
US4207414A (en) Polysaccharide antigens
EP0041897B1 (fr) Antigène de polysaccharide de streptocoque et vaccins
US20020044942A1 (en) Transfer factor composition and process for producing same
CN101113176A (zh) 鸡传染性法氏囊精制蛋黄冻干抗体的制备方法
CN118048275A (zh) 一株枯草芽孢杆菌及其在提高动物免疫力中的应用
KR880003632A (ko) 계란으로부터의 특이적항체함유재료 및 그 제조방법과 용도
JPS6121A (ja) ワクチンおよびその製造法
US20060182748A1 (en) Method of creating antivenom using Emus
CN1206243C (zh) 猪传染性胃肠炎病毒卵黄抗体和抗原及其制备
US4285930A (en) Antigens comprising immunostimulant adjuvants and their use in immunotherapy
JPH0789872A (ja) 腸原生動物のワクチン類
JPH11512746A (ja) 乳漿中の免疫グロブリンの単離方法
JP2000210050A (ja) 免疫調節活性分解物およびその製造方法並びにそれを用いた食品
WO1997029770A1 (fr) Vaccin contre la sarcocystose
US4902673A (en) Enhancing growth of bifidobacteria using soybean extract
RU2076734C1 (ru) Способ получения пероральной химической вакцины
Valsamidis et al. Immune response of European sea bass (Dicentrarchus labrax L.) against combination of antigens from three different pathogens
RU2077340C1 (ru) Способ получения специфической сыворотки для лечения, диагностики и профилактики вирусной геморрагической болезни кроликов и набор для диагностики болезни
JP4150631B2 (ja) 魚類冷水病ワクチン
JPH1192389A (ja) 免疫賦活剤
RU2101020C1 (ru) Препарат, обладающий иммуностимулирующим действием

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97528817

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载